CR Intrinsic Investors is one of SAC Capital's subsidiaries, and one of its foci is on the biopharmaceutical industry. CR Intrinsic has previously employed Mathew Martoma, a portfolio manager who was charged with insider trading by the SEC earlier this year. CR Intrinsic's $600 million settlement was the largest of its kind on record. The fund has an estimated $2 billion to $3 billion in assets under management.
Hedge Fund - Cr Intrinsic InvestorsGet Email Alerts
Sac Subsidiary Bio, Returns, Net Worth
|Fund Name:||Cr Intrinsic Investors|
|Change This QTR||0.00%|
News, Interviews and Investor Letters